AZ buys Ardea Biosciences for $1.26 Billion

Quote

Anonymous

Guest




Ahhhh! Finally a finger to put in the tiny hole in this damn. This should work about as long as Medimmune's finger. We are whole again and the best pharma company since sliced bread. NOT!!! its over guys.
 




So....

The deal with Amgen earlier this month and now this with Ardea.

Now the bidding war with GSK for the buyout of Amylin begins and will probably take closer to 5 billion to get.

Nice to have cash reserves!

Will CSA's actually rep new-to-market drugs for diabetes, cancer, obesity, lupis, gout, psoriasis, Crohn's, etc?
 




This just in: Stockholders have heated arguments at the last meeting...quote" Buy Anything" Just satisfy our needs......My grandparents would roll over in their graves if they could see what you guys have been up to. So with that order to buy, AZ found something for sales ARDEA, a small biotech with hopes in treating gout.....They also have a stake in treating leprosy in the formal penal colony in the french guyana that has 8 remaining patients. One stockholder was quoted' Thank God they bought something, My parents were getting very angry at me". STOP: Reuters
 








"It must not be forgotten that this is not the only news from AstraZeneca and that it is still a fully functioning pharmaceutical company. Just recently, the company released the competitively priced blood pressure drug, Dutoprol. The drug only needs to be taken once a day and is a convenient alternative for most high blood pressure sufferers. AstraZeneca also took the unorthodox approach of launching the drug at the wholesale acquisition price directly to the consumer population, meaning that it competes well in terms of price against similar medications. The price of $15.90 stands with or without medical coverage. The drug is projected to generate enormous sales, which could mean big things for the company.

Earlier this year, AstraZeneca also won a lawsuit that allowed it to continue producing the antipsychotic drug Seroquel, despite the fact that competitors insisted that the patent had expired. This means that AstraZeneca will have yet another successful drug going forward, at least until the patent expires in 2017."
 




Anonymous said:
Guess this happened early this morning. Deal should close in second or third quarter this year and bring new drugs to the pipeline. Looks like a new gout drug and two cancer treatment combination drugs. I apologize ahead of time to all the doomsday people.

http://www.marketwatch.com/story/ardea-agrees-to-astrazenecas-32-share-bid-2012-04-23?siteid=msn

http://www.thestreet.com/story/1150...s-for-126b-hot-trends.html?puc=msn&cm_ven=msn
Click to expand...

Would agree that with AZ's current cash hoard that purchasing compounds is a doable strategy. Throw enough on the wall and some should stick. Don't wait until the cash flow slides, which it eventually will. There will still be a dip, but perhaps enough to emerge into the light. Possibly sufficient to give Publicis and the CSO's enough to do down the road.
 




The deal with Ardea is AstraZeneca’s largest acquisition in five years, but it may be the first of many more purchases, according to Bloomberg.

http://www.bloomberg.com/news/2012-...uy-ardea-biosciences-for-1-26-billion-1-.html

“We’re building some momentum here in R&D,” Mackay, told the news service in a telephone interview. “I would be disappointed if we didn’t announce further deals by the end of this year. We’ve taken our hits but we’re turning a corner.”
 








Sounds like the plan is in motion and there will be a lot of aquistions this year.

Good news if you were lucky enough to keep your job. Can't see AZ spending this much to bring more drugs in the pipeline and not keeping an experienced sales force to market them.
 




















Anonymous said:
hmm...how many ex AZ higher-ups will "somehow" find a cush job to land in at Ardea? 1.26B creates a nice landing place for a lot of insiders.
Click to expand...

Poor Ardea. They have no idea of the cancer that is about to destroy their culture and well being, let alone how clinical research progresses from here. The Borg must assimilate.
 








Top Bottom
Back
Quote